|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2001-2-22
|
|
pubmed:abstractText |
Partial correction of anaemia with recombinant human erythropoietin (rHuEpo) has been shown to markedly improve the general condition and quality of life of predialysis patients, but the effects of rHuEpo therapy on blood pressure and the rate of progression of chronic renal failure (CRF) are still disputed. In particular, no study evaluated the time duration until the start of maintenance dialysis in treated patients, compared to untreated predialysis patients.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0931-0509
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
307-12
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11158405-Aged,
pubmed-meshheading:11158405-Anemia,
pubmed-meshheading:11158405-Cohort Studies,
pubmed-meshheading:11158405-Disease Progression,
pubmed-meshheading:11158405-Erythropoietin,
pubmed-meshheading:11158405-Female,
pubmed-meshheading:11158405-Humans,
pubmed-meshheading:11158405-Kidney,
pubmed-meshheading:11158405-Kidney Failure, Chronic,
pubmed-meshheading:11158405-Male,
pubmed-meshheading:11158405-Middle Aged,
pubmed-meshheading:11158405-Recombinant Proteins,
pubmed-meshheading:11158405-Renal Replacement Therapy,
pubmed-meshheading:11158405-Retrospective Studies,
pubmed-meshheading:11158405-Time Factors
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients.
|
|
pubmed:affiliation |
Department of Nephrology and INSERM U 507, Necker Hospital, Paris, France.
|
|
pubmed:publicationType |
Journal Article
|
